Amorchem
Amorchem is a private equity and venture capital firm established in 1997 and based in Montreal, Canada. The firm focuses on investing in the life sciences sector, particularly in genomics, biotechnology, and therapeutics for diseases such as cancer, infectious diseases, inflammation, and diabetes. Amorchem primarily targets promising life science projects originating from universities and research centers in Quebec, employing an innovative model that finances research-stage projects to achieve pre-clinical proof-of-concept. The firm invests in various forms, including common stock and convertible securities, and often seeks a Board seat to actively participate in the growth of its portfolio companies. Amorchem's investment strategy emphasizes both early-stage and later-stage financing, and while it may act as a sole investor, it generally prefers to engage in syndicated deals. The firm primarily operates in Canada, the United States, and Europe, with a commitment to maximizing the commercial potential of quality academic research.
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists. Founded in 2015, the company aims to address various health conditions, including Prader-Willi syndrome, Type-1 diabetes, obesity, and other metabolic disorders such as non-alcoholic steatohepatitis. Inversago's approach seeks to overcome limitations associated with earlier generations of CB1 blockers, thereby maximizing their therapeutic potential. By advancing new drug candidates, Inversago Pharma is positioned to provide healthcare professionals and patients with effective treatment options for metabolic and fibrotic disorders.
SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.
SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.
SpecificiT’s unique approach is centered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.
Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.